Aptinyx Inc. (APTX)
Stock Price:
$4.99 USD
0.03 (0.60%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
227.82M |
| Revenue (ttm) |
3.60M |
| Net Income (ttm) |
-55.41M |
| Shares Out |
45.66M |
| EPS (ttm) |
-1.53 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$4.99 |
| Previous Close |
$4.96 |
| Change ($) |
0.03 |
| Change (%) |
0.60% |
| Day's Open |
5.00 |
| Day's Range |
4.51 - 5.20 |
| Day's Volume |
635,541 |
| 52-Week Range |
1.60 - 5.28 |
More Stats
| Market Cap |
227.82M |
| Enterprise Value |
106.62M |
| Earnings Date (est) |
Aug 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
45.66M |
| Float |
22.69M |
| EPS (basic) |
-1.55 |
| EPS (diluted) |
-1.53 |
| FCF / Share |
-1.13 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
659,325 |
| Short Ratio |
1.86 |
| Short % of Float |
2.51% |
| Beta |
1.46 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
63.34 |
| PB Ratio |
1.53 |
| Revenue |
3.60M |
| Operating Income |
-57.42M |
| Net Income |
-55.41M |
| Free Cash Flow |
-49.55M |
| Net Cash |
121.20M |
| Net Cash / Share |
2.65 |
| Gross Margin |
-1,130.41% |
| Operating Margin |
-1,596.44% |
| Profit Margin |
-1,540.40% |
| FCF Margin |
-1,377.45% |
| ROA |
-26.74% |
| ROE |
-43.09% |
| ROIC |
-6,924.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
8 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$10.39*
(108.22% upside)
Low
7.00
Current: 4.99
High
15.00
Target: 10.39
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 3.67 | 6.57 | 4.96 | 9.79 |
| Revenue Growth | -44.19% | 32.49% | -49.33% | - |
| Gross Profit | 3.67 | 6.57 | 4.96 | 9.79 |
| Operating Income | -59.61 | -54.89 | -32.23 | -17.72 |
| Net Income | -57.41 | -53.28 | -32.07 | -15.48 |
| Shares Outstanding | 33.56 | 20.20 | 5.20 | 4.90 |
| Earnings Per Share | -1.71 | -2.64 | -6.17 | -3.16 |
| Operating Cash Flow | -52.09 | -47.45 | -32.74 | -19.72 |
| Capital Expenditures | -0.04 | -0.41 | -1.58 | -0.37 |
| Free Cash Flow | -52.13 | -47.86 | -34.31 | -20.09 |
| Cash & Equivalents | 99.03 | 151 | 92.14 | 16.95 |
| Net Cash / Debt | 99.03 | 151 | 92.14 | 16.95 |
| Assets | 106 | 156 | 97.32 | 18.65 |
| Liabilities | 5.17 | 6.30 | 4.65 | 4.55 |
| Book Value | 101 | 149 | -39.72 | -8.55 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aptinyx Inc. |
| Country |
United States |
| Employees |
43 |
| CEO |
Norbert G. Riedel |
Stock Information
| Ticker Symbol |
APTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: APTX |
| IPO Date |
June 21, 2018 |
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc to develop a compound for the treatment of major depressive disorder. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.